Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity

Xueyuan Zhou1, Felix Klaus Geyer2, Jeffrey Takimoto1

  • 1Drug Discovery and Development, Fuse Biotherapeutics, Woburn, MA, United States.

Frontiers in Immunology
|January 5, 2026
PubMed

Related Concept Videos